A new startup from one of the key scientists at Google DeepMind exits stealth today with $50 million in funding.

Latent Labs hopes to take computational biology one step further. The company is developing foundation AI models that don’t merely predict the shape of proteins, but rather generate new protein designs from scratch. It hopes to use those designs to support the development of new medicines.

As part of the funding, Latent Labs aims to leverage generative artificial intelligence to computationally create novel therapeutic molecules, such as antibodies and enzymes, to improve molecular features.

The company is developing generative AI methods to design proteins from scratch, with applications in drug discovery and biotechnology.

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein structure prediction. While its roots lie in AlphaFold, the company’s focus extends beyond structure determination – modeling how molecules interact to accelerate drug design.